DOCSLIB.ORG

RBM12 Shrna (H) Lentiviral Particles: Sc-76364-V

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RBM12 Shrna (H) Lentiviral Particles: Sc-76364-V SANTA CRUZ BIOTECHNOLOGY, INC. RBM12 shRNA (h) Lentiviral Particles: sc-76364-V BACKGROUND APPLICATIONS Proteins containing RNA recognition motifs, including various hnRNP proteins, RBM12 shRNA (h) Lentiviral Particles is recommended for the inhibition of are implicated in the regulation of alternative splicing and protein components RBM12 expression in human cells. of snRNPs. The RBM (RNA-binding motif) gene family encodes proteins with an RNA binding motif that have been suggested to play a role in the modu- SUPPORT REAGENTS lation of apoptosis. RBM12 (RNA binding motif protein 12), also known as Control shRNA Lentiviral Particles: sc-108080. Available as 200 µl frozen SWAN, HRIHFB2091 or KIAA0765, is a 932 amino acid protein which local- viral stock containing 1.0 x 106 infectious units of virus (IFU); contains an izes to the nucleus. RBM12 contains multiple proline-rich regions, transmem- shRNA construct encoding a scrambled sequence that will not lead to the brane domains and three RNA recognition motifs (RRM). It has been found specific degradation of any known cellular mRNA. that the genes for RBM12 and copine I (CPNE1) overlap at human chromosome location 20q11.22, sharing the promoter region and a 5'UTR (which are con- GENE EXPRESSION MONITORING served in human, zebrafish and mouse), suggesting that a functional interac- tion between the two genes may exist. RBM12 (B-12): sc-514258 is recommended as a control antibody for moni- toring of RBM12 gene expression knockdown by Western Blotting (starting REFERENCES dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500). 1. Nagase, T., Ishikawa, K., Suyama, M., Kikuno, R., Miyajima, N., Tanaka, A., Kotani, H., Nomura, N. and Ohara, O. 1998. Prediction of the coding To ensure optimal results, the following support reagents are recommended: sequences of unidentified human genes. XI. The complete sequences of 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz 100 new cDNA clones from brain which code for large proteins in vitro. Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ DNA Res. 5: 277-286. Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluo- 2. Stover, C., Gradl, G., Jentsch, I., Speicher, M.R., Wieser, R. and Schwaeble, rescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 W. 2001. cDNA cloning, chromosome assignment, and genomic structure (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 of a human gene encoding a novel member of the RBM family. Cytogenet. or UltraCruz® Hard-set Mounting Medium: sc-359850. Cell Genet. 92: 225-230. 3. Online Mendelian Inheritance in Man, OMIM™. 2002. Johns Hopkins RT-PCR REAGENTS University, Baltimore, MD. MIM Number: 607179. World Wide Web URL: Semi-quantitative RT-PCR may be performed to monitor RBM12 gene expres- http://www.ncbi.nlm.nih.gov/omim/ sion knockdown using RT-PCR Primer: RBM12 (h)-PR: sc-76364-PR (20 µl). 4. Maris, C., Dominguez, C. and Allain, F.H. 2005. The RNA recognition motif, Annealing temperature for the primers should be 55-60° C and the extension a plastic RNA-binding platform to regulate post-transcriptional gene expres- temperature should be 68-72° C. sion. FEBS J. 272: 2118-2131. BIOSAFETY 5. Yang, W., Ng, P., Zhao, M., Wong, T.K., Yiu, S.M. and Lau, Y.L. 2008. Promoter-sharing by different genes in human genome—CPNE1 and Lentiviral particles can be employed in standard Biosafety Level 2 tissue RBM12 gene pair as an example. BMC Genomics 9: 456. culture facilities (and should be treated with the same level of caution as with any other potentially infectious reagent). Lentiviral particles are repli- CHROMOSOMAL LOCATION cation-incompetent and are designed to self-inactivate after transduction and integration of shRNA constructs into genomic DNA of target cells. Genetic locus: RBM12 (human) mapping to 20q11.22. RESEARCH USE PRODUCT The purchase of this product conveys to the buyer the nontransferable right RBM12 shRNA (h) Lentiviral Particles is a pool of concentrated, transduction- to use the purchased amount of the product and all replicates and derivatives ready viral particles containing 3 target-specific constructs that encode 19- for research purposes conducted by the buyer in his laboratory only (whether 25 nt (plus hairpin) shRNA designed to knock down gene expression. Each the buyer is an academic or for-profit entity). The buyer cannot sell or other- 6 vial contains 200 µl frozen stock containing 1.0 x 10 infectious units of virus wise transfer (a) this product (b) its components or (c) materials made using (IFU) in Dulbecco’s Modified Eagle’s Medium with 25 mM HEPES pH 7.3. this product or its components to a third party, or otherwise use this product Suitable for 10-20 transductions. Also see RBM12 siRNA (h): sc-76364 and or its components or materials made using this product or its components RBM12 shRNA Plasmid (h): sc-76364-SH as alternate gene silencing products. for Commercial Purposes. STORAGE PROTOCOLS Store lentiviral particles at -80º C. Stable for at least one year from the See our web site at www.scbt.com for detailed protocols and support date of shipment. Once thawed, particles can be stored at 4º C for up to products. one week. Avoid repeated freeze thaw cycles. Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com.
Load more

Recommended publications
  • Small Cell Ovarian Carcinoma: Genomic Stability and Responsiveness to Therapeutics
    Gamwell et al. Orphanet Journal of Rare Diseases 2013, 8:33 http://www.ojrd.com/content/8/1/33 RESEARCH Open Access Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics Lisa F Gamwell1,2, Karen Gambaro3, Maria Merziotis2, Colleen Crane2, Suzanna L Arcand4, Valerie Bourada1,2, Christopher Davis2, Jeremy A Squire6, David G Huntsman7,8, Patricia N Tonin3,4,5 and Barbara C Vanderhyden1,2* Abstract Background: The biology of small cell ovarian carcinoma of the hypercalcemic type (SCCOHT), which is a rare and aggressive form of ovarian cancer, is poorly understood. Tumourigenicity, in vitro growth characteristics, genetic and genomic anomalies, and sensitivity to standard and novel chemotherapeutic treatments were investigated in the unique SCCOHT cell line, BIN-67, to provide further insight in the biology of this rare type of ovarian cancer. Method: The tumourigenic potential of BIN-67 cells was determined and the tumours formed in a xenograft model was compared to human SCCOHT. DNA sequencing, spectral karyotyping and high density SNP array analysis was performed. The sensitivity of the BIN-67 cells to standard chemotherapeutic agents and to vesicular stomatitis virus (VSV) and the JX-594 vaccinia virus was tested. Results: BIN-67 cells were capable of forming spheroids in hanging drop cultures. When xenografted into immunodeficient mice, BIN-67 cells developed into tumours that reflected the hypercalcemia and histology of human SCCOHT, notably intense expression of WT-1 and vimentin, and lack of expression of inhibin. Somatic mutations in TP53 and the most common activating mutations in KRAS and BRAF were not found in BIN-67 cells by DNA sequencing.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Downloads/ (Accessed on 17 January 2020)
    cells Review Novel Approaches for Identifying the Molecular Background of Schizophrenia Arkadiy K. Golov 1,2,*, Nikolay V. Kondratyev 1 , George P. Kostyuk 3 and Vera E. Golimbet 1 1 Mental Health Research Center, 34 Kashirskoye shosse, 115522 Moscow, Russian; [email protected] (N.V.K.); [email protected] (V.E.G.) 2 Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilova Street, 119334 Moscow, Russian 3 Alekseev Psychiatric Clinical Hospital No. 1, 2 Zagorodnoye shosse, 115191 Moscow, Russian; [email protected] * Correspondence: [email protected] Received: 5 November 2019; Accepted: 16 January 2020; Published: 18 January 2020 Abstract: Recent advances in psychiatric genetics have led to the discovery of dozens of genomic loci associated with schizophrenia. However, a gap exists between the detection of genetic associations and understanding the underlying molecular mechanisms. This review describes the basic approaches used in the so-called post-GWAS studies to generate biological interpretation of the existing population genetic data, including both molecular (creation and analysis of knockout animals, exploration of the transcriptional effects of common variants in human brain cells) and computational (fine-mapping of causal variability, gene set enrichment analysis, partitioned heritability analysis) methods. The results of the crucial studies, in which these approaches were used to uncover the molecular and neurobiological basis of the disease, are also reported. Keywords: schizophrenia; GWAS; causal genetic variants; enhancers; brain epigenomics; genome/epigenome editing 1. Introduction Schizophrenia is a severe mental illness that affects between 0.5% and 0.7% of the human population [1]. Both environmental and genetic factors are thought to be involved in its pathogenesis, with genetic factors playing a key role in disease risk, as the heritability of schizophrenia is estimated to be 70–85% [2,3].
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • Supplemental Material 1
    SUP. FIGURE S1 DAPI NFAT Merge DMSO Ac­5SGlcNAc Figure S1. Inhibition of OGT does not prevent nuclear translocation of NFAT. Jurkat cells !"#$%&'()*+(!!,-.'/012"#..(3'4056'7(+('"+(#"(3'7,"8'9:';<'5=29>/%=45='?+'@<>A'B?+'CD' 8+!E''F(%%!'7(+('"8(-'*%#"(3'?-'#-",2F@GHF@ID2=?#"(3'=?J(+!%,*!'B?+'G:'K,-!E''5B"(+'B,)#",?-L' =(%%!'7(+('#-#%&M(3'$&'=?-B?=#%'K,=+?!=?*&E SUP. FIGURE S2 Labeled Unlabeled Labeled Unlabeled 1h 18h ­Az ­PEG 1h 19h ­Az ­PEG !"#$%"#&'( ­ + ­ + + + !"#$%"#&'( ­ + ­ + + + 110 EWSR1 160 *34+&5 80 &,/ 160 )*+-2$ 160 110 )*+,& 80 60 &,/ 160 110 80 0"1"- RUNX1 110 80 60 60 50 160 SP1 160 110 ELF1 110 80 160 NUP98 110 80 )*+&-. &,/ Figure S2. PEG mass tags allow visualization of O­GlcNAc stoichiometry. 5K PEG mass tags were affixed to O­GlcNAc groups on proteins from control or activated T cells via enzy­ matic labeling with azide and copper­free click chemistry. Proteins were then analyzed for shifts in electrophoretic mobility by immunoblot. For the unlabeled control samples, either the azide (­Az) or PEG (­PEG) reagent was omitted during the labeling procedure. Note that HCFC1 appears as multiple bands because the protein is expressed as a single polypeptide that under­ goes proteolytic processing. UBAP2L appears as two bands in the unlabeled control samples due to alternative splicing. Table S1. Details of 133 higher confidence and 81 lower confidence O-GlcNAc glycoproteins1. Confidence Uniprot ID Symbol Specificity Chi Higher P55265 ADAR 100% 9.11E-04 Higher Q09666 AHNAK 92% 2.36E-16 Higher Q8IWZ3 ANKHD1 100% 1.19E-03 Higher
    [Show full text]
  • Genetics of Gene Expression: 2010 Lab
    Genetics of gene expression: 2010 lab VJ Carey July 28, 2010 Contents 1 eQTL concepts and discovery tools 2 1.1 Checking for informative variants for a specified gene . .3 1.2 Components of the workflow; refinements . .4 1.2.1 Data representation: smlSet .....................6 1.2.2 Analysis: snp.rhs.tests; permutation testing . .8 1.2.3 Context: GenomicRanges and rtracklayer .............9 2 Comprehensive eQTL surveys: performance issues 11 2.1 A study of genes coresident on chromosome 20 . 11 2.2 Expanding to genes on multiple chromosomes . 13 2.3 Exercises . 15 3 Investigating allele-specific expression with RNA-seq data 17 3.1 Thedata.................................... 17 3.2 Filtering to \coding SNP"; checking for de novo variants . 18 3.3 Assessing allelic imbalance in transcripts harboring SNPs . 20 3.4 Checking consistency of findings with GENEVAR expression arrays . 23 3.5 Exercises . 24 4 Appendix: samtools pileup format, from samtools distribution site 25 5 Session information 26 1 Figure 1: A schematic illustrating various nonexclusive mechanisms by which DNA variants can affect transcript abundance (Williams et al., 2007). 1 eQTL concepts and discovery tools The basic concern in the lab is the relationship between structural variation in DNA and variation in mRNA abundance. DNA variants of interest are primarily SNP as identified through • direct genotyping in the Sanger sequencing paradigm (yielding HapMap phase II genotypes, for example) • array-based genotyping (yielding HapMap phase III) • NGS-based variant calling (as provided for 1000 genomes (1KG)) • hybrids of array-based and imputed genotypes (imputation to the 1KG panel) mRNA variation is typically characterized using gene expression microarrays, but RNA- seq can also be considered.
    [Show full text]
  • Introducing Gene Deletions by Mouse Zygote Electroporation of Cas12a/Cpf1
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2019 Introducing gene deletions by mouse zygote electroporation of Cas12a/Cpf1 Dumeau, Charles-Etienne ; Monfort, Asun ; Kissling, Lucas ; Swarts, Daan C ; Jinek, Martin ; Wutz, Anton Abstract: CRISPR-associated (Cas) nucleases are established tools for engineering of animal genomes. These programmable RNA-guided nucleases have been introduced into zygotes using expression vectors, mRNA, or directly as ribonucleoprotein (RNP) complexes by different delivery methods. Whereas mi- croinjection techniques are well established, more recently developed electroporation methods simplify RNP delivery but can provide less consistent efficiency. Previously, we have designed Cas12a-crRNA pairs to introduce large genomic deletions in the Ubn1, Ubn2, and Rbm12 genes in mouse embryonic stem cells (ESC). Here, we have optimized the conditions for electroporation of the same Cas12a RNP pairs into mouse zygotes. Using our protocol, large genomic deletions can be generated efficiently by electroporation of zygotes with or without an intact zona pellucida. Electroporation of as few as ten zygotes is sufficient to obtain a gene deletion in mice suggesting potential applicability of thismethod for species with limited availability of zygotes. DOI: https://doi.org/10.1007/s11248-019-00168-9 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-181145 Journal Article Published Version The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License. Originally published at: Dumeau, Charles-Etienne; Monfort, Asun; Kissling, Lucas; Swarts, Daan C; Jinek, Martin; Wutz, Anton (2019).
    [Show full text]
  • Chromosomal Microarray Analysis in Turkish Patients with Unexplained Developmental Delay and Intellectual Developmental Disorders
    177 Arch Neuropsychitry 2020;57:177−191 RESEARCH ARTICLE https://doi.org/10.29399/npa.24890 Chromosomal Microarray Analysis in Turkish Patients with Unexplained Developmental Delay and Intellectual Developmental Disorders Hakan GÜRKAN1 , Emine İkbal ATLI1 , Engin ATLI1 , Leyla BOZATLI2 , Mengühan ARAZ ALTAY2 , Sinem YALÇINTEPE1 , Yasemin ÖZEN1 , Damla EKER1 , Çisem AKURUT1 , Selma DEMİR1 , Işık GÖRKER2 1Faculty of Medicine, Department of Medical Genetics, Edirne, Trakya University, Edirne, Turkey 2Faculty of Medicine, Department of Child and Adolescent Psychiatry, Trakya University, Edirne, Turkey ABSTRACT Introduction: Aneuploids, copy number variations (CNVs), and single in 39 (39/123=31.7%) patients. Twelve CNV variant of unknown nucleotide variants in specific genes are the main genetic causes of significance (VUS) (9.75%) patients and 7 CNV benign (5.69%) patients developmental delay (DD) and intellectual disability disorder (IDD). were reported. In 6 patients, one or more pathogenic CNVs were These genetic changes can be detected using chromosome analysis, determined. Therefore, the diagnostic efficiency of CMA was found to chromosomal microarray (CMA), and next-generation DNA sequencing be 31.7% (39/123). techniques. Therefore; In this study, we aimed to investigate the Conclusion: Today, genetic analysis is still not part of the routine in the importance of CMA in determining the genomic etiology of unexplained evaluation of IDD patients who present to psychiatry clinics. A genetic DD and IDD in 123 patients. diagnosis from CMA can eliminate genetic question marks and thus Method: For 123 patients, chromosome analysis, DNA fragment analysis alter the clinical management of patients. Approximately one-third and microarray were performed. Conventional G-band karyotype of the positive CMA findings are clinically intervenable.
    [Show full text]
  • CPNE1 Is a Target of Mir-335-5P and Plays an Important Role in The
    Tang et al. Journal of Experimental & Clinical Cancer Research (2018) 37:131 https://doi.org/10.1186/s13046-018-0811-6 RESEARCH Open Access CPNE1 is a target of miR-335-5p and plays an important role in the pathogenesis of non-small cell lung cancer Haicheng Tang1,2,4†, Jianjie Zhu1,2,3†, Wenwen Du1,2†, Shunlin Liu1, Yuanyuan Zeng1,2,3, Zongli Ding1, Yang Zhang1,2, Xueting Wang1,2, Zeyi Liu1,2,3* and Jianan Huang1,2,3* Abstract Background: Despite advances in diagnosis and treatment, the survival of non-small cell lung cancer (NSCLC) patients remains poor. There is therefore a strong need to identify potential molecular targets for the treatment of NSCLC. In the present study, we investigated the function of CPNE1 in the regulation of cell growth, migration and invasion. Methods: Quantitative real-time PCR (qRT-PCR) was used to detect the expression of CPNE1 and miR-335-5p. Western blot and immunohistochemical assays were used to investigate the levels of CPNE1 and other proteins. Flow cytometry was used to determine cell cycle stage and apoptosis. CCK-8 and clonogenic assays were used to investigate cell proliferation. Wound healing, migration and invasion assays were used to investigate the motility of cells. A lung carcinoma xenograft mouse model was used to investigate the in vivo effects of CPNE1 overexpression. Results: We observed that knockdown of CPNE1 and increased expression of miR-335-5p inhibits cell proliferation and motility in NSCLC cells, and found that CPNE1 was a target of miR-335-5p. In addition, our data indicated that CPNE1 inhibition could improve the clinical effects of EGFR-tyrosine kinase inhibitors.
    [Show full text]
  • Ggtools 2011: Leaner Software for Genetics of Gene Expression
    GGtools 2011: leaner software for genetics of gene expression VJ Carey (stvjc at channing.harvard.edu) August 25, 2011 Contents 1 Introduction; major changes 2 2 A simple exploration of eQTL for a selected gene 2 2.1 Filtering an smlSet for a chromosome-wide test . .2 2.2 Executing tests and interrogating the results . .3 2.3 Visualization .................................4 2.4 Checking coincidence with other genomic features . .8 3 Supporting comprehensive testing 10 3.1 The default behavior of eqtlTests ..................... 10 3.2 Reducing the memory footprint for comprehensive `same chromosome' tests 11 3.3 Acquiring test results within specified intervals . 13 4 Working with multiple populations 16 5 Session information 17 1 1 Introduction; major changes Since its introduction in 2006, GGtools has provided a number of data structures and tools for exploratory data analysis and hypothesis testing in expression genetics. Since 2006, Bioconductor's facilities for representing genomes and for exploiting advanced ideas in computing and statistical modeling have evolved considerably, and many components of GGtools/GGBase need to be discarded to promote use of new facilities. The following major changes have been made. • smlSet instances should not be used for genotyping panels of more than one mil- lion loci. A packaging discipline has been introduced. An expression genetics experiment should be managed in a package in which expression data are held in an ExpressionSet instance in the data folder, and snpStats SnpMatrix instances are stored in inst/parts. After installation, the getSS function constructs an smlSet instance on the fly { typically with modest memory footprint because only a fraction of available loci are held in memory.
    [Show full text]
  • The DNA Sequence and Comparative Analysis of Human Chromosome 20
    articles The DNA sequence and comparative analysis of human chromosome 20 P. Deloukas, L. H. Matthews, J. Ashurst, J. Burton, J. G. R. Gilbert, M. Jones, G. Stavrides, J. P. Almeida, A. K. Babbage, C. L. Bagguley, J. Bailey, K. F. Barlow, K. N. Bates, L. M. Beard, D. M. Beare, O. P. Beasley, C. P. Bird, S. E. Blakey, A. M. Bridgeman, A. J. Brown, D. Buck, W. Burrill, A. P. Butler, C. Carder, N. P. Carter, J. C. Chapman, M. Clamp, G. Clark, L. N. Clark, S. Y. Clark, C. M. Clee, S. Clegg, V. E. Cobley, R. E. Collier, R. Connor, N. R. Corby, A. Coulson, G. J. Coville, R. Deadman, P. Dhami, M. Dunn, A. G. Ellington, J. A. Frankland, A. Fraser, L. French, P. Garner, D. V. Grafham, C. Grif®ths, M. N. D. Grif®ths, R. Gwilliam, R. E. Hall, S. Hammond, J. L. Harley, P. D. Heath, S. Ho, J. L. Holden, P. J. Howden, E. Huckle, A. R. Hunt, S. E. Hunt, K. Jekosch, C. M. Johnson, D. Johnson, M. P. Kay, A. M. Kimberley, A. King, A. Knights, G. K. Laird, S. Lawlor, M. H. Lehvaslaiho, M. Leversha, C. Lloyd, D. M. Lloyd, J. D. Lovell, V. L. Marsh, S. L. Martin, L. J. McConnachie, K. McLay, A. A. McMurray, S. Milne, D. Mistry, M. J. F. Moore, J. C. Mullikin, T. Nickerson, K. Oliver, A. Parker, R. Patel, T. A. V. Pearce, A. I. Peck, B. J. C. T. Phillimore, S. R. Prathalingam, R. W. Plumb, H. Ramsay, C. M.
    [Show full text]